News

ImaginAb, Inc. and Eurogentec S.A. Collaborate to Produce Antibody Fragments in Pichia

January 31, 2011

Los Angeles, January 31, 2011— ImaginAb, Inc. and Eurogentec S.A. announce a development collaboration to establish a novel system for producing engineered antibody fragments. The two companies will produce ImaginAb’s optimized antibody fragments with Eurogentec’s high-performance Pichia pastoris expression system. Leveraging Eurogentec’s expertise in cGMP manufacturing of recombinant proteins, the collaboration will accelerate the development of ImaginAb's rich pipeline of targeted molecular imaging agents for the diagnosis and treatment management of cancer and autoimmune diseases.

“With our rapidly expanding pharma client base worldwide, ImaginAb is leveraging multiple manufacturing technologies to increase our capacity for fast, reliable protein production,” said Dr. Christian Behrenbruch, CEO of ImaginAb. “Eurogentec’sPichia technology has the potential to enable us to take a fresh look at how we do extremely rapid and cost-effective translation into humans with our antibody fragment technology.”

Dr. Philippe Cronet, CSO of Eurogentec commented, “We are very committed to exploring new manufacturing strategies for ImaginAb’s unique products. Our technology platform is well suited to a variety of recombinant proteins including the important class of antibody fragment proteins such as those under development by ImaginAb”.

About ImaginAb

Founded in 2007 by UCLA Faculty (Drs. Robert Reiter, Anna Wu and Christian Behrenbruch), ImaginAb, Inc. is a biotechnology company specializing in the development of engineered antibody fragments for diagnostic imaging and novel therapeutic applications. The company has a significant pipeline of clinical products in development oriented towards unmet needs in cancer and immunology. ImaginAb is also developing a range of pre-clinical (animal imaging) reagents for use with microPET, microSPECT and optical imaging systems, and partners on a selective basis with biopharmaceutical companies with an interest in developing companion imaging agents for therapeutic antibody products. For more information about ImaginAb, visit www.imaginab.com.

About Eurogentec

Eurogentec is a cGMP accredited Contract Manufacturing Organization (CMO) offering process development and cGMP manufacturing services since 1994. Eurogentec manufactures recombinant proteins, plasmids, vaccines and conjugates in compliance with EU 2003/94/EC and US FDA 21CFR 210 and operates a full-service, state-of-the-art cGMP facility located in Belgium. In 2010, Eurogentec became part of Kaneka Corporation, Osaka, Japan. For more information about Eurogentec, visit www.eurogentec.com.

Contacts:

ImaginAb:

Celia Adelson
Business Development
+1 (310) 258 2411
Celia@ImaginAb.com

Eurogentec:
Florence Xhonneux
Business Development
+32 4 366 61 02
fl.xhonneux@eurogentec.com